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Choroid plexus tumors (CPT) are intraventricular neoplasms accounting for 10% of all 
primary central nervous system tumors in dogs. They are frequently classified according to 
the human WHO classification into choroid plexus papilloma (CPP, grade I), atypical CPP 
(aCPP, grade II), and choroid plexus carcinoma (CPC, grade III). Histological features 
observed in canine CPT such as increased vascular density (IVD) and glomeruloid 
microvascular proliferation (GMVP) are not part of the WHO classification. This multi-
centric study aimed to investigate tumor-associated vascular hyperplasia in dogs by 
determining the prevalence of GMVP and IVD in 52 canine CPT and their association with 
tumor grade. In addition, the expression of angiogenic factors was assessed by 
immunohistochemistry in 25 tumors to investigate the pathogenesis of tumor-associated 
vascular hyperplasia. Based on the classical histological hallmarks, this study of 52 CPT 
identified 22 (42%) CPP (grade I) and 30 of (58%) CPC (grade III). GMVP was more 
prevalent in CPC (13/30; 43%) than CPP (1/22; 4%), whereas IVD occurred to a similar 
extent in CPP and CPC. Desmoplasia was more common in CPC (19/30; 63%) than CPP 
(2/22; 9%), and similarly, the proliferative index (PI) of neoplastic epithelium was 
significantly higher in CPC (5.14%) than CPP (0.94%). The majority of CPT expressed 
platelet-derived growth factor (PDGF), PDGFRa, PDGFRb, and vascular endothelial 
growth factor (VEGF) irrespective of tumor grade or tumor-associated vascular 
hyperplasia. These results suggest that tumor- associated GMVP, desmoplasia, and PI 
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Choroid plexus tumors (CPT) are intraventricular neoplasms arising from the choroid 
plexus epithelium. In animals, these tumors occur most commonly in dogs and account for 
approx- imately 10% of all canine primary brain tumors.10 Due to their histological 
similarity to the human counterpart, in the current literature, canine CPT7,10,17,20,24,31 
are frequently graded in analogy to the human WHO current classification of central 
nervous system (CNS) tumors14 into choroid plexus papilloma (CPP, grade I), atypical 
choroid plexus papilloma (aCPP, grade II), and choroid plexus carcinoma (CPC, grade 
III).31 In humans, CPC is a highly aggressive malignant tumor compared to CPP and 
aCPP, and tumor grade currently dictates the use of appropriate treatment modalities.13 
Little, though, is known about the predictive value of the human grading system regard- 
ing the biological behavior and prognosis of canine choroid plexus tumors due to lack of 
prospective studies in this species. Angiogenic supply within a neoplasm is fundamental 
for tumor growth and metastatic potential.1,34 Tumor neovascularization occurs through 
several mechanisms, including vessel coop- tion, classical angiogenesis, and 
vasculogenesis,14 and it is well established that tumor progression from a premalignant to 
a malignant phenotype is dependent on angiogenesis.5 Accordingly, tumor-related 
vascular patterns such as increased vascular density (IVD) and glomeruloid microvascular 
prolif- eration (GMVP) have been described for human CNS tumors, primarily occurring in 
gliomas.26 While IVD is described in low-grade infiltrating astrocytomas (grade II) and 
character- ized by increased density of normal-appearing vessels com- pared to the 
normal brain,5 GMVP occurs in high-grade gliomas like oligodendroglioma grade III and 
glioblastoma both in humans and dogs.10 Hence, it is used as a histopathological 
hallmark of malignancy. Similarly, GMVP in human cancer patients is associated with 
aggressive tumor behavior, shorter survival, and increased clinical recurrence rates in non- 
CNS tumors like melanoma, breast, endometrial, and prostate cancers27 and 
chemoresistance in breast cancer.1 Morphologically, GMVP consists of tortuous vascular 
channels lined by multilayered and mitotically active endothelial cells, pericytes, and 
smooth muscle cells and is also known by the term glomeruloid bodies due to its resem- 
blance to renal glomeruli.14 Ultrastructural analysis of GMVP demonstrated that vascular 
channels are lined with hyperplas- tic endothelial cells, a basal lamina, and an incomplete 
layer of pericytes.5 Pathogenetically speaking, GMVP ontogenesis is likely the result of an 
upregulation of vascular endothelial growth factor (VEGF)5,9 and platelet-derived growth 
factor (PDGF).18,33 We observed vascular hyperplasia in a subset of canine CPT.17 
Therefore, the aims of the current study are to describe the prevalence and characteristics 
of GMVP and IVD in canine CPT, investigate their association with malignant forms of 
CPT, and yield insights into tumor-associated vas- cular ontogenesis by investigating the 
expression of angiogenesis-stimulating growth factors (VEGF, PDGF) and tyrosine kinase 
receptors.  
Material and Methods  
Cases and Tissues  
Fifty-two cases of canine CPT collected at postmortem were included in this retrospective 
study (1960–2015). The cases were collected from the diagnostic neuropathology archives 
of the Division of Neurological Sciences, Department of Clin- ical Research and Veterinary 
Public Health, University of Bern; Department of Pathology, Microbiology and Immunol- 
ogy, School of Veterinary Medicine, University of California– Davis; and Department of 
Veterinary Medicine, University of Perugia. Inclusion criteria were a histological diagnosis 
of choroid plexus tumor and brain or spinal tissue adjacent to the tumor to assess tumor-
related vascular patterns. Six histologi- cally normal choroid plexuses (NCP) from dogs 
without neu- rological disorders were included as control material.  
Histology-Based Tumor Grading  
Tumors were available as formalin-fixed and paraffin- embedded tissue. Three mm-thick 
sections were cut from paraffin blocks and routinely stained with HE. All available slides 
containing brain tissue were included in the evaluation. Tumors were graded according to 
the human WHO 2016 clas- sification14 (Table 1).  
Microscopically, CPP closely resembles the healthy non- neoplastic choroid plexus, but 
cells tend to be more crowded or stratified. The neoplastic epithelium loses the normal 
cob- blestone appearance of choroid plexus epithelium, being more columnar and 
organized in papilliform projections supported by delicate fibrovascular connective tissue 
fronds.14 Atypical CPP is defined by an increased mitotic count and may exhibit up to 2 
additional features of malignancy.14 CPC shows frank features of malignancy as listed in 
Table 1.14 Additional fea- tures recorded included brain invasion, intraventricular and 
subarachnoid spread, ependymal changes, hydrocephalus, and abundant tumor-
associated collagenous stroma (desmoplasia). Since benign CPP may seed neoplastic 
cells into the cerebrospinal fluid (CSF), distant tumor spread (drop metastasis) and 
minimal brain invasion are not canonically used to differentiate CPP from CPC.14 The 
mitotic count was performed with a light microscope using a 40  objective and lenses with 
a field number of 20 (area per field of 0.196 mm2). Tumor size was measured in 
millimeters along the major axis.  
This study classified tumor-associated angiogenesis into either IVD, characterized by an 
increased number of vessels with a single lumen and normal vessel wall anatomy, or 
GMVP, characterized by a glomerulus-like tortuous aggregation of blood vessels.5 The 
presence/absence of IVD and GMVP in the tumor stroma and within the parenchyma adja- 
cent to the tumor were evaluated.  
Western Blot  
Normal choroid plexus, lung, and brain (VEGF, PDGF, PDGFRa) were used to test the 
cross-reaction of antibodies with canine tissues. Each sample consisted of 100 mg of 
tissue mechanically homogenized in 900 ul of RIPA buffer (sodium deoxycholate 0.1%, 5 
mM Tris-HCl pH 7.2, 15 mM NaCl, 1 mM EDTA pH 8, 0.005% SDS, 0.1% NP-40) to obtain 
10% (w/v) tissue homogenates. Homogenates were centrifuged at 1000 g for 5 minutes to 
pellet cell debris. Supernatants were resuspended in Laemmli buffer and heated at 99 C 
for 5 min- utes. Protein electrophoresis was done at 150 volts for 85 min- utes using 15% 
sodium dodecylsulphate–polyacrylamide (SDS-PAGE) gels for VEGF/PDGF and 8% SDS-
PAGE gels for platelet-derived growth factor receptor alpha (PDGFRa) and platelet-
derived growth factor receptor beta (PDGFRb). Proteins were transferred to nitrocellulose 
membranes by applying 85 volts for 1 hour. Nonspecific binding sites were blocked with 
5% milk solution for 1 hour, and proteins were probed overnight at 4 C with antibodies 
against PDGF, PDGFRa, PDGFRb, and VEGF (Suppl. Table S1). Proteins of interest were 
detected by incubation with a secondary HRP- labeled anti-rabbit antibody diluted at 
1:3000 (DAKO P0448) for 30 minutes. Binding sites were revealed with a commercial 
chemiluminescent substrate (ECL prime, GE Healthcare Life Sciences). A membrane 
without the primary antibody was used as negative control. Western blot membranes were 
imaged with the LAS3000 luminescent image analyzer (Fuji) and the AIDA software 
package (Raytest, Version 5.1).  
Immunohistochemistry  
tissue to test the specificity and sensitivity of antibodies included a lymph node (anti-Ki67), 
brain vessels (anti- PDGFRb), and lung (for anti-PDGF, anti-PDGFRa, anti- VEGF, anti-
aSMA, and anti-vWF).  Expression of PDGF, PDGFRa, PDGFRb, and VEGF was 
evaluated in neoplastic and healthy choroid plexus epithelium if available, GMVP, IVD, 
and normal vessels of the brain following a subjective scoring system established by 
Nupponen et al.18 Accordingly, the percentage of immunostained cells was 
semiquantitatively determined as follows: 0 (absent), 1 (<10%), 2 (10%–50%), 3 (51%–
80%), and 4 (81%–100%), and the intensity of the immunostaining as 0 (absent), 1 (weak), 
2 (distinct), and 3 (strong). The immunolabeling of aSMA and vWF in GMVP and IVD was 
qualitatively recorded as either present or absent. The Ki67 proliferative index (PI) (ratio of 
Ki67-positive nuclei from the total number of nuclei present) was determined by examining 
10 high power fields (0.237 mm2) in CPT and normal choroid plexus and from the 
evaluation of at least 100 cells in GMVP, using the cell counter plugin in the ImageJ 
software (http:// imagej.nih.gov/ij/). Unfortunately, in IVD or normal blood ves- sels, a 
comparable number of cells could not be evaluated due to the small number of cellular 
nuclei (less than 100), and therefore, Ki67 positivity was assessed by counting individual 
cells. The immunohistochemical slides were evaluated by a blinded single examiner 
(L.V.M.) and cross-checked by a sec- ond examiner (A.O).  
Statistical Analysis  
The statistical analysis was performed with the GraphPad Prism 5 statistical software 
(GraphPad Software, Inc.). Because data were not normally distributed, continuous data 
were expressed as median value and analyzed with the nonpara- metric Mann-Whitney 
test to compare 2 groups and with the nonparametric Kruskal-Wallis test followed by 
Dunn’s multi- ple comparisons test to compare more than 2 groups. Catego- rical data 
were examined either with the chi-square or Fisher’s exact test depending on the number 
of groups and the sample size. A P value  .05 was considered as significant.  
Results  
The Proliferative Index Correlates With Histological Grade  
This study identified 22 of 52 (42%) CPP and 30 of 52 CPC (58%) in dogs by following the 
human WHO histological clas- sification of CPT.14 No canine aCPP was diagnosed. 
Histolo- gical features of NCP, CPP, and CPC are shown in Suppl. Figs. S1, S2, and S3. 
Anatomic localization and histological features are given in Table 2. No primary site was 
detected in the brain in 5 cases with multiple spinal subarachnoid masses.  
Desmoplasia was more frequent in CPC (65%) (Suppl. Fig. S3) than CPP (9%; P 1⁄4 .0001 
Fisher’s exact test). Simi- larly, brain invasion (CPC 1⁄4 77%; CPP 1⁄4 22%; P < .0001  
Twenty-five canine CPTs and normal choroid plexuses from 6 non-neurologic dogs were 
immunohistochemically tested for alpha smooth muscle actin (aSMA), Von Willebrand 
factor (vWF), Ki67, VEGF, PDGF, PDGFRa, and PDGFRb (see Suppl. Table S1 for 
antibody details) to label smooth muscle and endothelial cells and proliferating cells and 
evaluate the expression of growth factors, respectively. Slides contained tumor tissue or 
NCP plus surrounding brain parenchyma. Slides were deparaffinized in xylol and 
rehydrated after immer- sion in different gradients of ethanol. The endogenous perox- 
idase was blocked by immersion in 3% H2O2 in methanol for 30 minutes at room 
temperature. For the detection of PDGF, PDGFRa, PDGFRb, and vWF, enzymatic antigen 
retrieval consisted of digestion with 50 ml Proteinase K (19.2 mg/ml, Roche) in 50 ml TBS 
for 15 minutes in a water bath at 37 C. For the detection of Ki67, aSMA, and VEGF, heat 
antigen retrieval was performed by boiling tissue slides in pH 6.0 citrate buffer at 95 C 
(Ki67, aSMA: 20 minutes, VEGF: 45 minutes) using a laboratory microwave, followed by 
cooling at room temperature for 20 minutes. All tissue sections were incubated with the 
primary antibodies overnight at 4 C. Bind- ing sites were revealed using the streptavidin-
biotin-peroxidase reaction (LSAB DAKO Kit K500) and 3-amino-9- ethylcarbazole (AEC) 
as the chromogen (DAKO Kit K500). Slides were counterstained with Ehrlich’s 
haematoxylin. As negative control, the primary antibody was replaced with an irrelevant, 
isotype-matched antibody to control for nonspecific binding of the secondary antibody. 
Positive control canine  
Fisher’s exact test) and intraventricular (CPC 1⁄4 27%; CPP 1⁄4 4%) and subarachnoid 
(CPC 1⁄4 23%; CPP 1⁄4 0%) spread (P 1⁄4 .001 Fisher’s exact test) were more prevalent in 
CPC. In contrast, the histological grade was not associated with tumor size or location. 
Additionally, the prevalence of hydro- cephalus internus was similar in CPP (90%) and 
CPC (82%; P 1⁄4 .68 Fisher’s exact test), and ependymal changes (flattening and erosion) 
were present in all CPTs.  
While Ki67 was only expressed in 0.15% (range, 0%– 0.37%) of normal choroid plexus 
epithelial cells, the PI was higher in neoplastic choroid plexus epithelium (Suppl. Figs. S4–
S6). The Ki67 PI was higher in CPC than CPP (P 1⁄4 .0033, Mann-Whitney t test), with 
5.14% positive cells (range, 1.55%–24.75%) in CPC compared to 0.94% cells (range, 
0.59%–1.64%) in CPP (Fig. 1).  
Tumor-Associated Angiogenesis  
Tumor-associated angiogenesis was observed in 63% of CPT and occurred in 2 forms: 
IVD (61%) and GMVP (27%) (Figs. 2–4) (Table 2). While IVD was not associated with 
tumor grade (P 1⁄4 .14, Fisher’s exact test), GMVP occurred more frequently in CPC (43%) 
compared to CPP (4%) (P 1⁄4 .011, Fisher’s exact test). All tumors with GMVP exhibited 
concurrent IVD. Both IVD and GMVP were consis- tently observed in the subependymal 
brain parenchyma adja- cent to the tumor and occasionally within the tumor stroma. In 5 
cases, extensive GMVP was observed in the subependymal parenchyma along the 
ventricular system at sites distant from the primary tumor and occasionally lining the entire 
ventricular system of the brain.  
GMVP occurred more frequently in CPT with necrosis (46%) than tumors without necrosis 
(12%) (P 1⁄4 .012, Fisher’s exact test). However, necrotic areas had no apparent spatial 
relationship (co-localization) with GMVP. No association was found between increased 
vascular density and necrosis (P 1⁄4 .17, Fisher’s exact test). In addition, tumor-associated 
angiogenesis was not associated with tumor size (P 1⁄4 .06 Mann-Whitney test) or 
hydrocephalus (P 1⁄4 .39 Fisher’s exact test). Of the histological features occurring most 
frequently in CPCs, only GMVP was associated with tumoral brain invasion (P 1⁄4 .024, 
chi-square) and PI (P 1⁄4 .006, Mann-Whitney test) but not with spread along the CSF 
spaces. Desmoplasia was not associated with any of these features.  
All endothelial cells regardless of the types of vasculature expressed aSMA in mural cells 
(Figs. 5–7). Similarly, all types of vasculature were positive for vWF (Figs. 8–10). However, 
compared to normal vasculature and IVD, GMVP vessels were lined by multiple layers of 
aSMA positive mural cells. Addi- tionally, while normal vessels and IVD expressed Ki67 in 
sin- gle cells only (Fig. 11, Fig. 12), GMVP showed a PI of 5.75% in mural and endothelial 
cells (range, 0%–8.5%) (Fig. 13).  
Intratumoral and Vascular Expression of Growth Factors and PDGF Tyrosine Kinase 
Receptors  
Antibodies against VEGF, PDGF, PDGFRa, and PDGFRb pro- duced bands at the 
expected molecular weights in Western blot analysis and a specific signal in paraffin-
embedded control tissues indicating their cross-reaction with the canine antigens. Anti-
PDGFRa did not produce any specific WB band in the brain, while with anti-PDGF a 
specific band was lacking in NCP (Suppl. Figs. S7–S10).  
Expression of growth factors and receptors were immuno- histochemically assessed in 6 
NCP and 25 CPT (6 CPP, 19 CPC). Generally, growth factors and their receptors were 
expressed in choroid plexus tumors independently of the grade. No association was found 
between the expression of angiogen- esis factors and the Ki67 labeling index, the size of 
the neo- plasm, or the presence of IVD and GMVP.  
VEGF was strongly expressed in the cytoplasm of normal choroid plexuses (Fig. 14). 
Similarly, VEGF was intracytoplas- mically expressed in most CPT (Figs. 15, 16). 
However, 12% of tumors were negative for VEGF, and immunohistochemi- cally, the 
intensity of VEGF expression was lower in CPP (P 1⁄4 .018, Kruskal-Wallis test) and CPC 
(P 1⁄4 .004, Kruskal- Wallis test) than NCP. No difference in expression intensity was 
observed between CPP and CPC (Table 3).  
In normal brain capillaries, pericytes and endothelial cells expressed VEGF (Fig. 17). 
Expression intensity was apparently lower in pericytes and endothelial cells of IVD (Fig. 
18) and GMVP (Fig. 19) than normal capillaries but did not reach statistical significance (P 
1⁄4 .095 and P 1⁄4 .095, Kruskal- Wallis test).  
Two types of immunohistochemical staining patterns were observed with PDGF. Both 
normal and neoplastic choroid plexus epithelium exhibited similar diffuse cytoplasmic 
PDGF expression, which ranged between weak and moderate (Figs. 20, 21) (Table 3, P > 
.999, Kruskal-Wallis test for both CPP and CPC). The second staining pattern was 
characterized by multifocal neoplastic cell clusters with strong cytoplasmic  
PDGF immunostaining (Fig. 22) in 5 out of 19 CPCs. This staining pattern was not 
observed in either NCP or CPP. PDGF was expressed by astrocytes in the surrounding 
parenchyma and mural cells in the majority of normal brain vessels (Fig. 23). In contrast, 
expression was only rarely observed in tumor- associated vessels (in 2/25 CPTs) (Figs. 
24, 25). Also, the intensity of PDGF was higher in normal vessels than GMVP (P 1⁄4 .001, 
Kruskal-Wallis test), but no differences between normal vessels and IVD were detected (P 
1⁄4 .163, Kruskal- Wallis test).  
PDGFRa was intracytoplasmically expressed by most NCP (Fig. 26). Additionally, a weak 
multifocal membranous expres- sion was observed in 50% (Table 3) (Fig. 26). Similarly, 
cyto- plasmic expression was observed in CPTs, and approximately half of these tumors 
expressed the receptor on the epithelial apical surface (Figs. 27, 28). Although the 
intensity of expres- sion appeared to be increased in CPPs and CPCs (Figs. 27, 28) (Table 
3), the difference was not statistically significant (P 1⁄4 .687 and P 1⁄4 .111, Kruskal-Wallis 
test). Pericytes of normal capillaries weakly and inconsistently expressed PDGFRa in 24 of 
25 cases (Fig. 29), whereas the receptor was not expressed in pericytes of tumor-
associated vessels (Figs. 30, 31). Its expression was not picked up by WB of the brain 
possibly due to the multifocal and weak expression of PDGFRa in vessels (Suppl. Fig. S9).  
PDGFRb was expressed on the apical membrane of normal choroid plexuses and CPT. 
Expression intensity of PDGFRb was subjectively higher in CPP and CPC than NCP (Figs. 
32–34), but the differences were not statistically signif- icant (P 1⁄4 .789 and P > .999, 
Kruskal-Wallis test). PDGFRb was expressed in pericytes of normal brain vessels and 
tumor- associated vasculature (Figs. 35–37). The expression was equally intense between 
normal vessels, IVD, and GMVP (P 1⁄4 .243 and P 1⁄4 .393, Kruskal-Wallis test).  
Discussion  
Observations of tumor-associated angiogenesis have been pre- viously reported in canine 
CPT17,21 and rarely in human CPT4 with no associated significance. This study shows 
that GMVP is a prevalent feature found in canine CPCs. Morphologically, GMVP was 
characterized by tortuous vascular channels encased by thick layers of cells with an 
increased PI. Mural cells expressing markers of reactive pericytes aSMA and PDGFRb 
accounted for the majority, while vWF-expressing endothelial cells provided the minority of 
cells present in these proliferations. Such findings suggest pericyte abundance in GMVP 
as reported for human gliomas.3,28  
Based on the human WHO classification of brain tumors,14,31 which is frequently applied 
to canine CPT, our study included slightly more CPC than CPP. These results are 
concordant with previous studies on canine CPT.10,31 CPC exhibited significantly higher 
Ki67 indices than CPP indicating that the increased proliferative activity of canine CPC is a 
potential indicator of malignancy. These data are in line with a recent report on canine 
CPT20 and parallel human CPT data showing that the Ki-67 PI is an important prognostic 
indicator associated with the aggressiveness of human CPT, response to treatment, and 
clinical outcome.6,7,23,28,32 Additionally,  
desmoplasia and GMVP were observed clearly more frequent in CPC than CPP, 
suggesting that these 3 features could be included in the histological grading system as 
criteria for malignancy in CPT. Indeed, we found an association between GMVP and brain 
invasion suggesting that GMVP occurs in tumors with more aggressive behavior but not 
between GMVP and spread within the CSF spaces. Our observations regarding the 
occurrence of GMVP are in line with a study of human CPT that reported microvascular 
proliferation in carcinomas only4 and previous reports on canine CPTs, which found an 
increased frequency of vascular proliferation in high grade tumors.17,21 However, the 
canine studies also regularly observe vascular proliferation in CPP, which might be due to 
the fact that these studies did not distinguish between IVD and GMVP. Clearly, all canine 
CPT studies, including ours, suffer from the low number of tumor cases, and the partially 
different grading systems applied preclude the comparison of studies. Additionally, it is 
currently not clear whether the human WHO classification of human brain tumors reflects 
the biological behavior of canine CPT. Therefore, large- scale prospective studies are 
needed to ultimately define mor- phological features that correlate with the biological 
behavior of canine CPTs to confirm PI, desmoplasia, and GMVP as factors of malignancy.  
The pathogenetic mechanism of GMVP formation is a mat- ter of debate. In experimentally 
induced brain metastases, GMVP originate from preexisting capillaries that are induced to 
bend and loop their walls following adhesion of tumor cells, and there is no evidence of 
sprouting.8 Strikingly, in our case population, tumor-associated angiogenesis was 
frequently located in the subependymal brain parenchyma, also at distant sites, which 
does not support induction of GMVP by tumor cell adhesion. There was no association of 
subependymal GMVP with tumor size, hydrocephalus, or ependymal disruption, which 
argues against GMVP induction by mechanical stimulation. The subependymal localization 
of distant GMVP in absence of ependymal disruption at these sites argues for production 
and secretion of a soluble (growth) factor by CPT into the CSF causing GMVP following 
permeation through the ependymal lining. Indeed, intradermal GMVP has been experi- 
mentally induced by VEGF injections through the mechanism of sprouting angiogenesis.29 
Additionally, the induction of GMVP by VEGF is known in human astrocytomas.5 In these 
tumors, hypoxia and necrosis cause VEGF upregulation result- ing in vascular hyperplasia 
including GMVP,5 and hence, GMVP is frequently observed in the neighborhood of 
necrosis. In canine CPT, GMVP was more frequent in tumors with necrosis than tumors 
without, possibly suggesting that either GMVP is induced by hypoxia-induced tissue 
necrosis or GMVP are leaky, nonfunctional vessels causing hypoperfusion of neoplastic 
cells. However, unlike GMVP in gliomas, we did not observe any clear topographic 
association between GMVP and necrosis, making a causal link between these 2 events in 
CPT unlikely. In our study, VEGF was expressed in both nor- mal canine choroid plexus 
epithelium and CPT cells, yet CPT exhibited only low VEGF expression compared to NCP. 
Addi- tionally, VEGF expression was not associated with intratu- moral necrosis or GMVP, 
and only few endothelial cells were present in GMVP. Altogether, these results indicate 
that unlike gliomas, GMVP is independent of hypoxia-induced necrosis and VEGF 
expression in canine CPTs and its patho- genesis remains to be clarified. Similarly, GMVP 
formation is independent of VEGF expression in human melanoma, endo- metrial 
carcinoma,27 and non–small cell lung cancer.30 VEGF expression in the normal choroid 
plexus may be explained by its angiogenic phenotype that ensures the maintenance of 
endothelial fenestrations by the expression of pro-angiogenic factors.15,16 The decrease 
of VEGF expression intensity observed in CPT compared to NCP may therefore suggest 
tumor dedifferentiation. Two staining patterns were observed with anti-PDGF. The first 
pattern was observed in canine NCP and CPT and was characterized by rather weak 
cytoplasmic granular expression of PDGF. As the antibody did not produce a specific band 
in the WB analysis of NCP, the signal might be considered a non- specific reactivity of the 
antibody. Alternatively, the signal might be too weak to be detected by WB analysis. The 
second expression pattern was restricted to CPCs (5/19) and consisted of a strong 
intracytoplasmic signal in multifocal clusters of neoplastic cells, suggesting a possible 
(over)expression in a subset of malignant tumors, which warrants further investiga- tion. 
Prospective studies using WB analysis of fresh CPT tis- sue, not available in our study, are 
required to correctly interpret the PDGF staining patterns.  
The expression of PDGFRa and –Rb expression in CPT was similar to that in normal 
plexuses, which is in contrast to human CPT, in which increasing overexpression of the 
receptors has been found between grades.11,18,25 PDGFRb protein overex- pression in 
human CPT is related to PDGFRB gene amplifica- tion18 and associated with a shorter 
overall survival.19 We did not observe any association between expression of VEGF, 
PDGFB, PDGFRa, and PDGFRb and tumor grade or size, suggesting that these pathways 
are not exclusive growth factor signals for the proliferation of cancer cells and tumor 
progres- sion in canine CPTs. However, this has to be confirmed by further, more 
extensive studies.  
Physiologically, angiogenesis is promoted by various growth factors.12 A well-known 
signaling pathway operating the endothelial-pericyte cross-talk is the PDGF/PDGFR– 
dependent pathway during wound healing and in tumors.22 In the course of angiogenesis, 
PDGF is produced by sprouting endothelial cells and activates the receptor b on pericytes, 
sug- gestive of a paracrine mode of interaction between these 2 cell types.2,3,22 PDGF 
promotes the recruitment and proliferation of pericytes precursor cells.22 In our tumor 
population, PDGF was basically not expressed in tumor vessels but in neoplastic 
epithelium of a few CPC, representing a potential source of PDGF that may act on 
PDGFRb expressing pericytes of intra- tumoral and intracerebral vessels and stimulating 
their prolif- eration. However, no association was observed between strong tumoral PDGF 
expression and GMVP.  
In conclusion, the histological grade of canine CPTs corre- lates with higher Ki67 
proliferative indices, and the prevalence of GMVP and desmoplasia is strikingly higher in 
CPC. In contrast, no association was found between IVD and tumor grade. These results 
suggest that GMVP, desmoplasia, and Ki67 PI might be promising prognostic markers for 
canine CPT. Large-scale prospective studies based on clinico- pathological correlations 
and survival rates of canine patients with CPT should confirm our findings. The signaling 
pathways involved in GMVP of CPT await identification.  
Acknowledgements  
We thank Camille Monney, Manuela Bozzo, Erika Bu ̈ rgi, and Evelyne Rohrer for 
excellent technical support. Furthermore, we are grateful to Istvan Vajtai and Daniela 
Gorgas for constructive discussions.  
Author Contribution  
Brunetti B, Oevermann A, equal contribution.  
Declaration of Conflicting Interests  
The author(s) declared no potential conflicts of interest with respect to the research, 
authorship, and/or publication of this article.  
Funding  
The author(s) received no financial support for the research, author- ship, and/or 
publication of this article.  
References  
1. Akslen LA, Straume O, Geisler S, et al. Glomeruloid microvascular prolifera- tion is 
associated with lack of response to chemotherapy in breast cancer. Br J Cancer. 
2011;105(1):9–12.  
2. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 
2005;97(6):512–523.  
3. Armulik A, Genove ́ G, Betsholtz C. Pericytes: developmental, physiological, and 
pathological perspectives, problems, and promises. Dev Cell. 2011;21(2): 193–215.  
4. Barreto AS, Vassallo J, Queiroz Lde S. Papillomas and carcinomas of the choroid 
plexus: histological and immunohistochemical studies and comparison with normal fetal 
choroid plexus. Arq Neuropsiquiatr. 2004;62(3A):600–607.  
5. BratDJ,VanMeirEG.Glomeruloidmicrovascularproliferationorchestratedby VPF/VEGF: a 
new world of angiogenesis research. Am J Pathol. 2001;158(3): 789–796.  
6. Carlotti CG Jr, Salhia B, Weitzman S, et al. Evaluation of proliferative index and cell 
cycle protein expression in choroid plexus tumors in children. Acta Neuropathol. 
2002;103(1):1–10.  
7. Choi EJ, Sloma EA, Miller AD. Kir7.1 immunoreactivity in canine choroid plexus tumors. 
J Vet Diagn Invest. 2016;28(4):464–468.  
8. Do ̈me B, T ́ıma ́r J, Paku S. A novel concept of glomeruloid body formation in 
experimental cerebral metastases. J Neuropathol Exp Neurol. 2003;62(6): 655–661.  
9. Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med. 
2008;86(2):135–144.  
10. Higgins RJ, Bollen AW, Dickinson PJ, et al. Tumor of the nervous system. In: Meuten 
DJ, ed. Tumor in Domestic Animals. 5th ed. Ames, Iowa: Wiley Black- well; 2016:853–855.  
11. Koos B, Paulsson J, Jarvius M, et al. Platelet-derived growth factor receptor 
expression and activation in choroid plexus tumors. Am J Pathol. 2009;175(4): 1631–
1637.  
12. Kumar V, Abbas AK, Aster JC. Neoplasia. In: Kumar V, Abbas AK, Aster JC, ed. 
Robbins and Cotran Pathologic basis of disease. 9th ed. Philadelphia, PA: Elsevier 
Saunders; 2015:265–338.  
13. Lam S, Lin Y, Cherian J, et al. Choroid plexus tumors in children: a population- based 
study. Pediatr Neurosurg. 2013;49(6):331–338.  
14. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central 
Nervous System, WHO/IARC Classification of Tumours. 4th ed. Gen- eva: WHO; 2016.  
15. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor 
localization in the adult. Am J Pathol. 2006;168(2):639–648. 16. Maharaj AS, Walshe TE, 
Saint-Geniez M, et al. VEGF and TGF-beta are  
required for the maintenance of the choroid plexus and ependyma. J Exp Med.  
2008;205(2):491–501. 
17. Nentwig A, Higgins RJ, Francey T, et al. Aberrant E-cadherin, b-catenin, and  
glial fibrillary acidic protein (GFAP) expression in canine choroid plexus  
tumors. J Vet Diagn Invest. 2012;24(1):14–22. 
18. Nupponen NN, Paulsson J, Jeibmann A, et al. Platelet-derived growth factor receptor 
expression and amplification in choroid plexus carcinomas. Mod Pathol. 2008;21(3):265–
270.  
19. Raica M, Cimpean AM. Platelet-derived growth factor (PDGF)/PDGF receptors 
(PDGFR) axis as target for antitumor and antiangiogenic therapy. Pharmaceu- 
ticals. 2010;3(3):572–599.  
20. Reginato A, Girolami D, Menchetti L, et al. E-cadherin, N-cadherin expression and 
histologic characterization of canine choroid plexus tumors. Vet Pathol. 
2016;53(4):788–791.  
21. Ribas JL, Mena H, Braund KG, et al. A histologic and immunocytochemical study of 
choroid plexus tumors of the dog. Vet Pathol. 1989;26(1):55–64.  
22. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev  
Biol. 2011;55(3):261–268.  
23. Rickert CH, Paulus W. Tumors of the choroid plexus. Microsc Res Tech. 2001;  
52(1):104–111.  
24. Rossmeisl JH, Hall-Manning K, Robertson JL, et al. Expression and activity of  
the urokinase plasminogen activator system in canine primary brain tumors.  
Onco Targets Ther. 2017;10:2077–2085.  
25. Safaee M, Oh MC, Bloch O, et al. Choroid plexus papillomas: advances in  
molecular biology and understanding of tumorigenesis. Neuro Oncol. 2013;  
15(3):255–267.  
26. Stiver S. Angiogenesis and its role in the behavior of astrocytic brain tumors.  
Front Biosci. 2004;9:3105–3123.  
27. Straume O, Chappuis PO, Salvesen HB, et al. Prognostic importance  
of glomeruloid microvascular proliferation indicates an aggressive angiogenic 
phenotype in human cancers. Cancer Res. 2002;62(23): 6808–6811. 
 
28. Sun MZ, Oh MC, Ivan ME, et al. Current management of choroid plexus  
carcinomas. Neurosurg Rev. 2014;37(2):179–192. 
29. Sundberg C, Nagy JA, Brown LF, et al. Glomeruloid microvascular pro-  
liferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-
164 gene delivery. Am J Pathol. 2001;158(3): 1145–1160.  
30. Tanaka F, Oyanagi H, Takenaka K, et al. Glomeruloid microvascular proliferation is 
superior to intratumoral microvessel density as a prognos- tic marker in non-small cell lung 
cancer. Cancer Res. 2003;63(20): 6791–6794.  
31. Westworth DR, Dickinson PJ, Vernau W, et al. Choroid plexus tumors in 56 dogs 
(1985–2007). J Vet Intern Med. 2008;22(5):1157–1165.  
32. Wrede B, Hasselblatt M, Peters O, et al. Atypical choroid plexus papilloma: clinical 
experience in the CPT-SIOP-2000 study. J Neurooncol. 2009;95(3): 383–392.  
33. Yang J, Dombrowski SM, Deshpande A, et al. VEGF/VEGFR-2 changes in frontal 
cortex, choroid plexus, and CSF after chronic obstructive hydrocephalus. J Neurol Sci. 
2010;296(1–2):39–46.  
34. Zecchin A, Borgers G, Carmeliet P. Endothelial cells and cancer cells: meta- bolic 
partners in crime? Curr Opin Hematol. 2015;22(3):234–242.  
 
